β
Outcome MeasureOther

SCL-90-R

Symptom Checklist-90-Revised

4 Papers in Blossom

Clinical Thresholds

04
Non-clinical
Score 0–0
At-risk
Score 1–1
Clinical
Score 2–4

Outcome Data Across Studies

Reported results for SCL-90-R across 1 study with quantitative data.

Outcome data across 2 study arm–timepoint observations
SD
Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial
2025Secondary
Psilocybin 25 mg(experimental)28——Δ——
Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial
2025Secondary
Placebo(inactive)28——Δ——

Papers Using SCL-90-R

Open Accessindividual

Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial

This double-blind randomised clinical trial (n=37) found that a single dose of psilocybin (25mg) with brief psychotherapy did not significantly reduce alcohol relapse rates or consumption compared to placebo in patients with alcohol use disorder (AUD) at 4-week or 6-month follow-up, though psilocybin participants reported additional reductions in craving and temptation to drink, suggesting larger trials are needed to evaluate this approach for severely affected patients.

Published
Journal
EClinicalMedicine
Authors
Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Von Rotz, R., Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., Preller, K. H.
Open Accessindividual

LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up

In a planned 12‑month open‑label follow‑up of a double‑blind, placebo‑controlled crossover trial, LSD‑assisted therapy produced sustained, clinically significant reductions in anxiety and depression with large effect sizes lasting up to nearly two years after treatment. Participants also showed decreased neuroticism, increased extraversion and reported positive long‑term effects attributed to the psychedelic experience.

Published
Journal
BJPsych Open
Authors
Holze, F., Gasser, P., Müller, F., Strebel, M., Liechti, M. E.
Open Accessindividual

Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases

This double-blind cross-over study (n=12) showed that LSD (200 μg, 2 sessions) in combination with psychotherapy was safe to use and trended towards a positive effect on end-of-life anxiety.

Published
Journal
Journal of Nervous and Mental Disease
Authors
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., Brenneisen, R.
Open Accessindividual

The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study

In the first randomised controlled pilot trial, MDMA-assisted psychotherapy produced significantly greater reductions in Clinician-Administered PTSD Scale scores than placebo in 20 patients with chronic, treatment‑resistant post‑traumatic stress disorder (83% response vs 25%). There were no drug‑related serious adverse events, adverse neurocognitive effects or clinically significant blood pressure increases, suggesting MDMA may be a safe and effective adjunct to psychotherapy in refractory PTSD.

Published
Journal
Journal of Psychopharmacology
Authors
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., Doblin, R.

Quick Facts

Full Name
Symptom Checklist-90-Revised
Domain
Other
Papers Indexed
4
Score Range
0–4
Interpretation
Lower = better
Unit
points (GSI)
All Measures